Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma

Yumura, Masako; Nagano, Tatsuya; Jimbo, Naoe; Dokuni, Ryota; Kiriu, Tatsunori; Tanaka, Yugo; Tachihara, Motoko; Itoh, Tomoo; Maniwa, Yoshimasa; Nishimura, Yoshihiro; Kobayashi, Kazuyuki

doi:10.21873/anticanres.15595

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Downregulated ADH1B has been found in LIHC, and polymorphisms on ADH1B and ALDH2 had distinct indirect functions on the risk of LIHC ( Liu et al, 2016 ). ANXA10 is related to poor prognosis of patients with early gastric cancer, small bowel adenocarcinoma, and lung adenocarcinoma ( Ishikawa et al, 2020 ; Ishikawa et al, 2021 ; Yumura et al, 2022 ). As previously reported, the decreased level of ANXA10 was related to vascular invasion, early relapse, and dismal prognosis in synergy with p53 mutation in LIHC ( Liu et al, 2002 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of afatinib-associated ADH1B and potential small-molecule drugs targeting ADH1B for hepatocellular carcinoma

Zhou

Huang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Afatinib is an irreversible epidermal growth factor receptor tyrosine kinase inhibitor, and it plays a role in hepatocellular carcinoma (LIHC). This study aimed to screen a key gene associated with afatinib and identify its potential candidate drugs.Methods: We screened afatinib-associated differential expressed genes based on transcriptomic data of LIHC patients from The Cancer Genome Atlas, Gene Expression Omnibus, and the Hepatocellular Carcinoma Database (HCCDB). By using the Genomics of Drug Sensitivity in Cancer 2 database, we determined candidate genes using analysis of the correlation between differential genes and half-maximal inhibitory concentration. Survival analysis of candidate genes was performed in the TCGA dataset and validated in HCCDB18 and GSE14520 datasets. Immune characteristic analysis identified a key gene, and we found potential candidate drugs using CellMiner. We also evaluated the correlation between the expression of ADH1B and its methylation level. Furthermore, Western blot analysis was performed to validate the expression of ADH1B in normal hepatocytes LO2 and LIHC cell line HepG2.Results: We screened eight potential candidate genes (ASPM, CDK4, PTMA, TAT, ADH1B, ANXA10, OGDHL, and PON1) associated with afatinib. Patients with higher ASPM, CDK4, PTMA, and TAT exhibited poor prognosis, while those with lower ADH1B, ANXA10, OGDHL, and PON1 had unfavorable prognosis. Next, ADH1B was identified as a key gene negatively correlated with the immune score. The expression of ADH1B was distinctly downregulated in tumor tissues of pan-cancer. The expression of ADH1B was negatively correlated with ADH1B methylation. Small-molecule drugs panobinostat, oxaliplatin, ixabepilone, and seliciclib were significantly associated with ADH1B. The protein level of ADH1B was significantly downregulated in HepG2 cells compared with LO2 cells.Conclusion: Our study provides ADH1B as a key afatinib-related gene, which is associated with the immune microenvironment and can be used to predict the prognosis of LIHC. It is also a potential target of candidate drugs, sharing a promising approach to the development of novel drugs for the treatment of LIHC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of afatinib-associated ADH1B and potential small-molecule drugs targeting ADH1B for hepatocellular carcinoma

Zhou

Huang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…ANXA1 is known as an anti-inflammatory protein but is recognized to have a broader role in tumour cell biology beyond inflammation alone. ANXA1, located on human chromosome 9q21.13, is the first characterized member of the superfamily [12]. Transposition of ANXA1, which was found in oesophageal cancer, could affect the activities of arachidonic acid metabolism [34].…”

Section: Discussionmentioning

confidence: 99%

“…Annexins, including 12 family members, play a major role in the regulation of a broad range of physiological processes linked to cellular membranes [3]. Previous studies have revealed that the aberrant expression of ANXAs is frequently observed in various types of cancer, including cervical cancer [4], bladder cancer [5,6], breast cancer [7][8][9], gastric cancer [10], lung cancer [11,12], oral squamous cell carcinoma [13], hepatocellular carcinoma [14,15], and cholangiocarcinoma [16]. ANXAs may function as either oncogenes or suppressors depending on tumour biology.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma

Zhao

Chang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Annexins family (ANXAs), as a Ca2+-dependent phospholipid-binding protein superfamily, participates in a wide variety of biological activities and has been reported to be dysregulated in numerous types of human cancers. Evidence from cell lines and human tissues indicates that ANAXs are involved in kidney clear renal cell carcinoma (KIRC) tumorigenesis. However, their prognostic value and expression pattern associated with KIRC remain to be elucidated. Methods. We visited public databases, including ONCOMINE, Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan–Meier plotter, cBioPortal, and GeneMANIA, to conduct comprehensive bioinformatics analysis and tried to detect basic relationships between each Annexins family member and KIRC. Results. We found that the expression level of ANXA1/2/4/5/6/7/8/13 in clear renal cell carcinoma tissue was higher than that in the kidney tissue, while the expression level of ANXA3/9/11 in the former was lower than that in the latter. The expression level of ANXA7/8/13 is related to the stage of the tumour. Survival analysis using the Kaplan–Meier plotter database showed that a high transcription level of ANXA2/5/8/10 is related to a low overall survival rate (OS) in predicting KIRC patients. In contrast, high ANXA3/4/7/9/11/13 levels are associated with a high OS in these patients. Conclusions. Our study implies that ANXA4/8/13 are potential targets of precision therapy for patients with KIRC and that ANXA2/5/8/10 are new biomarkers for the prognosis of KIRC.

show abstract

“…In addition, ANXA10 has been proposed to be a tumor suppressor in NSCLC based on migration and invasion assays and in vivo studies conducted by Hung et al ( Hung et al, 2019 ). Opposing to this, high ANXA10 expression was detected in lung adenocarcinomas, and promoted the migration of A549 cells ( Yumura et al, 2022 ).…”

Section: Annexin A10mentioning

confidence: 99%

“…In relation to its oncopromoter role, ANXA10 has been proposed as a prognostic biomarker and therapeutic target in many tumor types. Of special interest, high ANXA10 expression was reported as an independent poor prognostic biomarker in lung adenocarcinoma ( Yumura et al, 2022 ), glioblastoma multiforme ( Xu et al, 2021 ), serous epithelial ovarian cancer ( Wang et al, 2019 ), pancreatic ductal adenocarcinoma ( Ishikawa et al, 2022b ), small bowel adenocarcinoma ( Ishikawa et al, 2021 ) and papillary thyroid cancer ( Liu X. et al, 2021 ). Interestingly, ANXA10 has also been proposed as a useful and highly specific biomarker for adenocarcinomas of the upper gastrointestinal tract and pancreatobiliary system, and also included in a panel of biomarkers to trace the origin of adenocarcinomas with unknown primary sites ( Lu et al, 2013 ).…”

Section: Annexin A10mentioning

confidence: 99%

Pathobiological functions and clinical implications of annexin dysregulation in human cancers

Prieto-Fernández

Menéndez

Otero-Rosales

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Annexins are an extensive superfamily of structurally related calcium- and phospholipid-binding proteins, largely conserved and widely distributed among species. Twelve human annexins have been identified, referred to as Annexin A1-13 (A12 remains as of yet unassigned), whose genes are spread throughout the genome on eight different chromosomes. According to their distinct tissue distribution and subcellular localization, annexins have been functionally implicated in a variety of biological processes relevant to both physiological and pathological conditions. Dysregulation of annexin expression patterns and functions has been revealed as a common feature in multiple cancers, thereby emerging as potential biomarkers and molecular targets for clinical application. Nevertheless, translation of this knowledge to the clinic requires in-depth functional and mechanistic characterization of dysregulated annexins for each individual cancer type, since each protein exhibits varying expression levels and phenotypic specificity depending on the tumor types. This review specifically and thoroughly examines the current knowledge on annexin dysfunctions in carcinogenesis. Hence, available data on expression levels, mechanism of action and pathophysiological effects of Annexin A1-13 among different cancers will be dissected, also further discussing future perspectives for potential applications as biomarkers for early diagnosis, prognosis and molecular-targeted therapies. Special attention is devoted to head and neck cancers (HNC), a complex and heterogeneous group of aggressive malignancies, often lately diagnosed, with high mortality, and scarce therapeutic options.

show abstract

Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma

Cited by 3 publications

References 0 publications

Identification of afatinib-associated ADH1B and potential small-molecule drugs targeting ADH1B for hepatocellular carcinoma

Identification of afatinib-associated ADH1B and potential small-molecule drugs targeting ADH1B for hepatocellular carcinoma

Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma

Pathobiological functions and clinical implications of annexin dysregulation in human cancers

Contact Info

Product

Resources

About